Analysts Set Tempus AI, Inc. (NASDAQ:TEM) Price Target at $56.00

Tempus AI, Inc. (NASDAQ:TEM) has been assigned an average rating of “Moderate Buy” from the twelve analysts that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $56.00.

A number of equities analysts have recently commented on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $70.00 price objective (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and increased their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Loop Capital boosted their price target on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Guggenheim began coverage on Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 price objective for the company. Finally, Wolfe Research began coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock.

Tempus AI Stock Up 1.5 %

NASDAQ TEM opened at $34.25 on Tuesday. The company’s fifty day moving average is $49.04 and its two-hundred day moving average is $46.62. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI has a 52-week low of $22.89 and a 52-week high of $79.49.

Insider Buying and Selling

In other news, EVP Andrew Polovin sold 51,504 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the completion of the transaction, the executive vice president now directly owns 246,085 shares in the company, valued at approximately $10,431,543.15. This represents a 17.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 187,655 shares of Tempus AI stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total value of $7,044,568.70. Following the sale, the chief executive officer now directly owns 9,557,283 shares in the company, valued at $358,780,403.82. The trade was a 1.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 845,041 shares of company stock worth $35,125,473.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of TEM. NEA Management Company LLC lifted its holdings in shares of Tempus AI by 17.8% in the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock worth $304,846,000 after purchasing an additional 813,169 shares in the last quarter. Novo Holdings A S purchased a new stake in Tempus AI in the 2nd quarter valued at $142,605,000. Revolution Growth Management Company Inc. purchased a new stake in shares of Tempus AI in the second quarter valued at about $128,133,000. ARK Investment Management LLC increased its stake in Tempus AI by 355.0% in the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock valued at $134,604,000 after buying an additional 1,855,459 shares during the last quarter. Finally, Alphabet Inc. bought a new position in shares of Tempus AI during the 2nd quarter worth approximately $54,289,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.